Do Hair Peptides Actually Work

HAIR & WIG SCIENCE SERIES

A HIASTI Clinical Education Publication

Peptides and Hair Loss

What the Research Actually Shows

An evidence review of the peptides marketed for hair loss and graying, organized by what the published research demonstrates and where its limits are.

Peptides are short chains of amino acids, and many act as signaling molecules that influence how cells behave. Several are marketed for hair. The strength of the evidence behind them varies widely from one peptide to the next, and much of it comes from cell cultures, animal models, or combination formulas rather than controlled human trials. This review reports what the published research shows, and where it stops.

BOTTOM LINE

Peptides may support scalp and follicle biology, but no peptide has been proven to replace FDA-approved treatments for androgenetic alopecia. Most peptide claims rely on early-stage research, small trials, animal studies, or combination formulas. For medical or extensive hair loss, peptides should be viewed as supportive, not curative.

The evidence baseline

For androgenetic alopecia, minoxidil and finasteride remain the best-established FDA-approved drug treatments, depending on patient sex, formulation, and clinical appropriateness. Peptide and growth-factor formulations are used off-label or sold as cosmetics and carry no such approval.

A 2025 review in the International Journal of Trichology surveyed the most heavily marketed topical hair actives, including peptide complexes, and found that most have been studied as combination formulas in small trials, often with limited sample sizes and industry funding. The review concluded that these actives may serve as add-on or alternative options, not as replacements for standard therapy.

Copper peptides (GHK-Cu and AHK-Cu)

What the research shows:  GHK-Cu is a copper-binding tripeptide that occurs naturally in human plasma, saliva, and urine, and declines with age, from roughly 200 nanograms per milliliter at age 20 to about 80 by age 60. A 2015 peer-reviewed review documented its roles in wound healing, collagen synthesis, and anti-inflammatory signaling.

In laboratory work, a tripeptide-copper complex stimulated the elongation of human hair follicles and increased dermal papilla cell proliferation and VEGF expression in cell and tissue culture (Pyo et al., 2007). Separately, copper ions were shown to inhibit type 1 5-alpha-reductase in vitro (Sugimoto et al., 1995).

What the research does not show:  The 5-alpha-reductase finding involved copper ions in a test tube, not proven suppression of DHT in human scalp. Robust human clinical trials on copper peptides for hair remain limited. A 2025 study reported hair regrowth in androgenetic alopecia after monthly sessions that combined copper peptides with minoxidil and dutasteride delivered by tattooing, but because the copper peptide was paired with two proven drugs, its independent effect cannot be separated out (JAAD International, 2025). The mechanistic and animal data are consistent, but they do not yet amount to proof of clinical hair regrowth in people.

Acetyl tetrapeptide-3 with biochanin A

What the research shows:  This peptide, usually paired with red clover extract in the complex marketed as Capixyl, has the strongest topical trial data among hair peptides. In a 24-week, randomized, triple-blind study of 32 people with mild-to-moderate androgenetic alopecia, a combination containing biochanin A, acetyl tetrapeptide-3, and ginseng showed hair-count results comparable to 3 percent minoxidil (Lueangarun and Panchaprateep, 2020). An industry-sponsored four-month study reported a 46 percent increase in the anagen-to-telogen ratio versus placebo.

What the research does not show:  Every one of these studies tested a combination formula. Because the peptide was paired with other active ingredients, the research cannot isolate how much benefit the peptide itself provided. Sample sizes were small, and some data comes from manufacturer technical files.

Biotinoyl tripeptide-1

What the research shows:  This peptide is common in hair serums and is proposed to support keratin production and follicle anchoring. Laboratory studies suggest effects on the structures around the follicle.

What the research does not show:  There is no robust standalone randomized trial isolating biotinoyl tripeptide-1 for hair growth in humans. Most available evidence sits within combination products, which limits what can be attributed to the peptide alone.

Thymosin beta-4 (marketed as TB-500)

What the research shows:  Thymosin beta-4 is an actin-binding peptide with documented roles in wound healing and angiogenesis. In rodents, it accelerated hair growth by activating hair follicle stem cells and promoting their migration (Philp et al., 2004), and transgenic mouse work linked it to hair growth through VEGF signaling (Gao et al., 2015).

What the research does not show:  The human evidence does not match the rodent results. In serum-free organ culture of human scalp follicles, thymic peptides including thymosin beta-4 inhibited hair shaft production rather than promoting it (Journal of Investigative Dermatology, 2012). There are no human clinical trials establishing that injected thymosin beta-4 grows hair, and it is widely sold only as a research compound.

Peptides marketed for graying hair

What the research shows:  Peptides promoted for graying, such as palmitoyl tetrapeptide-20 and acetyl hexapeptide-1, are built on the biology of the melanocortin pathway, in which signaling molecules like alpha-MSH influence pigment production. That pathway is real and well characterized.

What the research does not show:  Peer-reviewed clinical evidence that these peptides restore pigment in human hair is minimal. In one human follicle organ-culture study, thymic peptides did not increase follicle melanogenesis. Once a hair has fully lost its pigment, no peptide has been shown to reliably reverse it. This is a research frontier, not an established treatment.

Oral peptides (collagen and keratin)

What the research shows:  Hydrolyzed collagen peptides have randomized, placebo-controlled evidence for skin hydration and elasticity. A 12-week trial also reported improvements in scalp and hair condition, including a significant increase in a clinical grading score for healthy hair appearance (Reilly et al., 2024).

What the research does not show:  In that same trial, the 27.6 percent increase in total hair count versus placebo was not statistically significant. Hair-specific effects are weaker than the skin data, mechanisms are demonstrated mainly in preclinical models, and the bioavailability of orally ingested peptides for follicles remains debated. Ingested proteins and peptides are largely broken down during digestion, although some peptide fragments may be absorbed. How much of that activity meaningfully reaches the follicle remains uncertain.

The evidence, summarized

Grouping the peptides by the strength of the human evidence:

Established for androgenetic hair loss: minoxidil, finasteride when clinically appropriate, and hair transplantation for suitable candidates.

Supported but limited: copper peptide-containing approaches and acetyl tetrapeptide-3 complexes, studied mainly in small trials and combination formulas.

Preclinical or insufficient: injectable peptides for hair, peptides for graying, and most standalone serum claims.

Across the literature, peptides may support the follicular environment and hair quality, and a few have measurable effects in controlled settings. The published research does not show any peptide replacing the treatments proven for hair loss, or, where hair loss is medical or extensive, the role of a well-constructed cranial prosthesis.

In professional hair loss care, peptides belong in the category of supportive scalp and hair-quality ingredients, not proven stand-alone treatments for hair regrowth.

References

Listed most recent first.

1.  Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia. Frontiers in Pharmacology. 2026. Peptide and growth-factor formulations are used off-label, without FDA approval for AGA. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1776134/full

2.  Kuceki G, et al. Enhanced hair regrowth with five monthly sessions of minoxidil-dutasteride-copper peptides tattooing for androgenetic alopecia, assessed by artificial intelligence and blinded evaluators. JAAD International. 2025. (Copper peptide studied in combination with two proven drugs.) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11992372/

3.  Ding W, ed. Antihair loss peptides. In: Active Peptides for Skin Care. Academic Press; 2025:117-122. https://doi.org/10.1016/B978-0-443-30287-9.00008-0

4.  Topical alternatives for hair loss: beyond the conventional. International Journal of Trichology. 2025. National Library of Medicine, PMC12251978. https://pmc.ncbi.nlm.nih.gov/articles/PMC12251978/

5.  Reilly DM, Kynaston L, Naseem S, Proudman E, Laceby D. A clinical trial shows improvement in skin collagen, hydration, elasticity, wrinkles, scalp, and hair condition following 12-week oral intake of a supplement containing hydrolysed collagen. Dermatology Research and Practice. 2024;2024:8752787. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11254459/

6.  Androgenetic alopecia: therapy update. 2023. National Library of Medicine, PMC10173235. Topical minoxidil and oral finasteride are the only FDA-approved treatments. https://pmc.ncbi.nlm.nih.gov/articles/PMC10173235/

7.  Lueangarun S, Panchaprateep R. An herbal extract combination (biochanin A, acetyl tetrapeptide-3, and ginseng extracts) versus 3% minoxidil solution for the treatment of androgenetic alopecia: a 24-week, prospective, randomized, triple-blind, controlled trial. J Clin Aesthet Dermatol. 2020;13(10):32-37. https://pmc.ncbi.nlm.nih.gov/articles/PMC7840088/

8.  Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International. 2015;2015:648108. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508379/

9.  Gao X, Liang H, Hou F, et al. Thymosin beta-4 induces mouse hair growth. PLoS One. 2015;10(6):e0130040. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470810/

10.  Thymic peptides differentially modulate human hair follicle growth. Journal of Investigative Dermatology. 2012. (Human scalp follicle organ culture.) https://www.jidonline.org/article/S0022-202X(15)35747-X/fulltext

11.  Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research. 2007;30(7):834-839.

12.  Philp D, Nguyen M, Scheremeta B, et al. Thymosin beta 4 increases hair growth by activation of hair follicle stem cells. FASEB Journal. 2004;18(2):385-387.

13.  Sugimoto Y, et al. Inhibitory effect of copper (II) ions on type 1 5-alpha-reductase activity, in vitro. 1995.

© Hairline Illusions™ | HIASTI | Hair & Wig Science Series. All rights reserved. This article is for professional education and is not a substitute for individualized medical evaluation. No portion of this publication may be reproduced, distributed, transmitted, or excerpted in any form or by any means, including digital, print, or screenshot, without prior written permission from Hairline Illusions LLC.